Thrombosis and Haemostasis, Table of Contents Thromb Haemost 1976; 35(01): 261-263DOI: 10.1055/s-0038-1647951 Original Article Schattauer GmbH XXI Annual Meeting of the International Committee on Thrombosis and Haemostasis K. M Brinkhous Recommend Article Abstract Buy Article Full Text References References 1 Deutsch E, Brinkhous K. M, Lechner K, Hinnom S. eds. 1974; Thrombosis: Pathogenesis and Clinical Trials. Thrombosis et Diathesis Haemorrhagica Suppi 59 p. 352. 2 Koller F. The physiological function of heparin. p. 17. 3 Kiss J. Chemistry of heparin — a short review on recent chemical trends. p. 20. 4 Estes J. W, Poulin P. F. Pharmacokinetics of heparin - distribution and elimination. p. 26. 5 Abildgaard U. Heparin cofactor and antithrombin. p. 38. 6 Yin E. T. Effect of heparin on the neutralization of factor Xa and thrombin by the plasma alpha-2-globulin inhibitor. p. 43. 7 Rosenberg R. D. The effect of heparin on factor XIa and plasmin. p. 51. 8 Zucker M. B. Effect of heparin on platelet function. p. 63. 9 Lüscher E. F, Kaser-Glanzmann R. Platelet heparin-neutralizing factor platelet factor. 4 p. 66. 10 Markwardt F. Antilipemic action of heparin. p. 73. 11 Godal H. C. Heparin assay methods for control of in vivo heparin effects. p. 77. 12 Wessler S. Small doses of heparin and a new concept of hypercoagulability. p. 81. 13 Kakkar V. V. Low dose heparin in the prevention of venous thromboembolism. Rationale and results. p. 87. 14 McNicol G. P. Conventional uses of heparin. p. 97. 15 Nyman D, Thurnherr N, Duckert F. Heparin dosage in extracorporeal circulation and its neutralization. p. 102. 16 Lasch H. G, Heene D. H. Heparin therapy of diffuse intravascular coagulation DIC. p. 105. 17 Straub P. W. A case against heparin therapy of intravascular coagulation. p. 107. 18 Saliba M. J, Saliba R. J. Heparin in burns - dose related and dose dependent effects. p. 113. 19 Brinkhous K. M. XX annual meeting of the International Committee on Thrombosis and Haemostasis. p. 124. 20 Blombäck B. Report of the Subcommittee on Nomenclature. p. 126. 21 Abildgaard U. Report of the Task Force on Inhibitors of Blood Coagulation. p. 127. 22 Blombäck B. Report of the Task Force on Nomenclature of Fibrinogen-Fibrin Degradation Products. p. 141. 23 Ménaché D. Report of the Task Force on Clinical Use of factor IX Concentrates. p. 597. 24 Ménaché D. Factor IX concentrates. p. 600. 25 Hoofnagle J. H, Aronson D, Roberts H. Serologic evidence for hepatitis B virus infection in patients with hemophilia B - a multicenter study. p. 606. 26 Roberts H. R, Blatt P. M. Post-transfusion hepatitis following the use of prothrombin complex concentrates. p. 610. 27 Kingdon H. S, Lundblad R. L, Veltkamp J. J, Aronson D. L. Potentially thrombogenic materials in factor IX concentrates. p. 617. 28 Cash J. D, Dalton R. G, Middleton S, Smith J. K. Studies on the thrombo-genicity of Scottish factor IX concentrates in dogs. p. 632. 29 Kasper C. K. Thromboembolic complications. p. 642. 30 Ménaché D, Roberts H. R. Summary report and recommendations of the Task Force members and consultants. p. 645. 31 Day H. J, Holmsen H, Zucker M. B. Methods for separating platelets from plasma. p. 648. 32 Verstraete M. Registry of prospective clinical trials. p. 655.
